Loading clinical trials...

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation | Clinical Trials | Clareo Health

Back to clinical trial search

Active Not RecruitingPhase 1/2NCT07084311

Personalized Antisense Oligonucleotide for A Single Participant With ATN1 Gene Mutation

This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with dentatorubral-pallidoluysian atrophy (DRPLA) due to a heterozygous ...

Lead sponsor: n-Lorem Foundation•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE1/PHASE2

Enrollment1

Start dateOct 2024

Last updatedJul 24, 2025

Condition

Dentatorubral-Pallidoluysian Atrophy

Locations shown

Hawaii Pacific Neuroscience

Honolulu, Hawaii

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 24, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions